Loading the content... Loading depends on your connection speed!

Shopping Cart - $0.00

Respiratory Drugs Market Global Briefing 2017

Respiratory Drugs Market Global Briefing 2017

From $1,000.00

Including: Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations.
Covering: GlaxosmithKline Plc., AstraZeneca Plc., Merck & Co., Novartis AG, Johnson & Johnson, Gilead, Bayer AG, Boehringer Ingelheim GmbH, Teva Pharmaceuticals, Pfizer Inc.


Clear selection
SKU: 2281. Categories: , .
Description

The segments in the respiratory drugs market include anti-asthmatics and COPD drugs accounting for over 65% of the market and cough and cold preparations accounting for around 33% of the market.

Respiratory Drugs Market Global Briefing from the Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The market characteristics section of the report defines and explains the market.

The market size section gives the respiratory drugs market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the respiratory drugs market and suggests approaches.

Reasons to Purchase

• Get up to date information available on the respiratory drugs market globally.
• Identify growth segments and opportunities.
• Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
• Develop strategies based on likely future developments.
• Gain a global perspective on the development of the market.

 

Scope

Markets Covered: Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations.
Companies Mentioned: GlaxosmithKline Plc., AstraZeneca Plc., Merck & Co., Novartis AG, Johnson & Johnson, Gilead, Bayer AG, Boehringer Ingelheim GmbH, Teva Pharmaceuticals, Pfizer Inc.
Geographic scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Market value in $ billions.
Data segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Executive Summary
Respiratory diseases drugs market covers drugs that are used in the treatment of a wide range of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic and acute bronchitis, emphysema and cystic fibrosis. Some of the major drugs in the market include antimuscarinics, corticosteroids, Codral®, Coldrex® and Lemsip®. The market numbers in this briefing cover pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.

The global respiratory drugs market is expected to reach around $65 billion in 2020. Going forward, the rise in global air pollution levels will lead to higher number of respiratory diseases thus driving the respiratory drugs market.  

Growing Demand For Tamper-Resistant Pseudoephedrine (PSE) Products – The demand for PSE-containing cold, allergy, and sinus products is growing due to their effectiveness and convenience. PSE is an active ingredient found in various cold, allergy, and sinus drugs that can provide congestion relief. However, PSE-containing medicines are mostly sold as a prescription drug, as PSE can also be used for the illegal manufacture of methamphetamine, a recreational drug. This has led drug manufacturers to produce tamper-resistant PSE products. For instance, in March 2017, pharmaceutical companies Acura Pharmaceuticals Inc. and MainPointe Pharmaceuticals LLC entered into an agreement, enabling MainPointe Pharmaceuticals LLC to market NEXAFED and NEXAFED Sinus products in the US and Canada. These drugs utilize tamper-resistant PSE formulation to prevent the illicit production of methamphetamine.
Table of Contents
Respiratory Drugs Market Characteristics 5
Respiratory Drugs Market Historic Growth 6
Respiratory Drugs Market Forecast Growth 7
Respiratory Drugs Market Segmentation 8
Global Respiratory Drugs Market, Split By Segments, 2016, $ Billion 8
Anti-Asthmatics And COPD Drugs 8
Cough And Cold Preparations 9
Global Respiratory Drugs Market, Historic and Forecast, Split By Segments, 2012-2020 10
Respiratory Drugs Market Geography Regional and Country Comparison 11
Global Respiratory Drugs Market, Split By Regions, 2016 11
Global Respiratory Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 13
Global Respiratory Drugs Market, Split By Country, 2016 15
Global Respiratory Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 17
Respiratory Drugs Market Competitive Landscape 19
GlaxosmithKline Plc. 20
AstraZeneca Plc. 20
Merck & Co. 20
Novartis AG 20
Johnson & Johnson 20
Gilead 20
Bayer AG 20
Boehringer Ingelheim GmbH 20
Teva Pharmaceuticals 20
Pfizer Inc. 20
GlaxoSmithKline 21
AstraZeneca PLC 21
Merck & Co. 22
Respiratory Drugs Market Key Mergers And Acquisitions 24
AstraZeneca Acquired Almirall’s Respiratory Business 24
Recordati Acquired Italchimici S.p.A. 24
Mast Therapeutics, Inc. Merged With Savara 24
Vectura Merged With Skyepharma 24
Ruthigen Merged With Pulmatrix 24
Ario Pharma Acquired PharmEste’s TRPA1 Research Assets 24
Respiratory Drugs Market Trends And Strategies 25
Growing Demand For Tamper-Resistant Pseudoephedrine (PSE) Products 25
Resurgence Of Nasal Remedies For Treatment Of Cold 25
Development Of RMC-1 Drug For Respiratory Diseases Treatment 25
Collaborations In The Respiratory Diseases Drugs Market 25
Appendix 27
NAICS Definitions Of Industry Covered In This Report 27
Definition Of Market Covered In This Report 27
Abbreviations 27
Currencies 28
Research Methodology 28
Research Inquiries 29
The Business Research Company 29

List of Figures
Figure 1: Global Respiratory Drugs Market, Historic Market Size, 2012-2016, $ Billion 6
Figure 2: Global Respiratory Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion 7
Figure 3: Global Respiratory Drugs Market, Split By Segments, 2016, $ Billion 8
Figure 4: Global Respiratory Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020 10
Figure 5: Global Respiratory Drugs Market, Split By Region, 2016, $ Billion 11
Figure 6: Global Respiratory Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 13
Figure 7: Global Respiratory Drugs Market, Split By Country, 2016, $ Billion 15
Figure 8: Global Respiratory Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 17
Figure 9: Global Respiratory Drugs Market, Key Competitor Market Shares, 2016, Percentage (%) 19

List of Tables
Table 1: Global Respiratory Drugs Market, Historic Market Size, 2012-2016, $ Billion 6
Table 2: Global Respiratory Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion 7
Table 3: Global Respiratory Drugs Market, Split By Segments, 2016, $ Billion 8
Table 4: Global Respiratory Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020 10
Table 5: Global Respiratory Drugs Market, Split By Region, 2016, $ Billion 12
Table 6: Global Respiratory Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 13
Table 7: Global Respiratory Drugs Market, Split By Country, 2016, $ Billion 15
Table 8: Global Respiratory Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 17
Table 9: Global Respiratory Drugs Market, Key Competitor Market Shares, 2016, Percentage (%) 20
Get Customized Report
Please fill in your details. Our team will get back to you